BioLineRx Ltd (BLRX) - Total Assets
Based on the latest financial reports, BioLineRx Ltd (BLRX) holds total assets worth $39.80 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BioLineRx Ltd (BLRX) net assets for net asset value and shareholders' equity analysis.
BioLineRx Ltd - Total Assets Trend (2008–2024)
This chart illustrates how BioLineRx Ltd's total assets have evolved over time, based on quarterly financial data.
BioLineRx Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
BioLineRx Ltd's total assets of $39.80 Million consist of 69.7% current assets and 30.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.8% |
| Accounts Receivable | $3.86 Million | 9.9% |
| Inventory | $3.15 Million | 8.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $10.45 Million | 26.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how BioLineRx Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BioLineRx Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLineRx Ltd's current assets represent 69.7% of total assets in 2024, a decrease from 88.6% in 2008.
- Cash Position: Cash and equivalents constituted 26.8% of total assets in 2024, down from 52.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 2.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.
BioLineRx Ltd Competitors by Total Assets
Key competitors of BioLineRx Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
BioLineRx Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 1.52 | 2.15 |
| Quick Ratio | 1.93 | 1.37 | 2.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.86 Million | $12.89 Million | $12.24 Million |
BioLineRx Ltd - Advanced Valuation Insights
This section examines the relationship between BioLineRx Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -39.1% |
| Total Assets | $38.91 Million |
| Market Capitalization | $12.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioLineRx Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioLineRx Ltd's assets decreased by 39.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioLineRx Ltd (2008–2024)
The table below shows the annual total assets of BioLineRx Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $38.91 Million | -39.14% |
| 2023-12-31 | $63.92 Million | -16.31% |
| 2022-12-31 | $76.38 Million | -6.15% |
| 2021-12-31 | $81.39 Million | +72.11% |
| 2020-12-31 | $47.29 Million | -11.72% |
| 2019-12-31 | $53.57 Million | -4.74% |
| 2018-12-31 | $56.23 Million | -7.76% |
| 2017-12-31 | $60.97 Million | +56.57% |
| 2016-12-31 | $38.94 Million | -24.10% |
| 2015-12-31 | $51.30 Million | +41.85% |
| 2014-12-31 | $36.17 Million | +81.30% |
| 2013-12-31 | $19.95 Million | -17.93% |
| 2012-12-31 | $24.31 Million | -17.15% |
| 2011-12-31 | $29.34 Million | -32.80% |
| 2010-12-31 | $43.66 Million | +3.90% |
| 2009-12-31 | $42.02 Million | +37.14% |
| 2008-12-31 | $30.64 Million | -- |
About BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more